Veeda Clinical Research Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Veeda Clinical Research Limited's is preparing to launch its Initial Public Offering (IPO) with a substantial issue size of TBD. The offering comprises a fresh issue component of TBD.
The price band for the IPO has been set at TBD, providing investors with a range to place their bids. The minimum investment lot consists of TBD, making it accessible to both retail and institutional investors.
The subscription window for this public offering opens on TBD and will conclude on TBD. Following the subscription period, the share allotment is scheduled for TBD, with the official listing expected to commence on TBD on the NSE, BSE exchange.
Founded in April 2004, Veeda Clinical Research Limited is a contract research organization (CRO) that provides a wide range of services for drug development, including pre-clinical and clinical trials, bioavailability and bioequivalence studies, and testing for generics, biosimilars, and medical devices. The company offers services such as early and late-stage clinical trials, healthy volunteer studies, and biopharma analysis, supporting pharmaceutical companies throughout the development process. It has successfully undergone multiple global regulatory inspections by authorities like the US FDA, UK MHRA, WHO, and others, and serves a large international client base. As of September 30, 2024, the company had over 436 active clients and a strong track record of completed studies across different years, with a workforce of around 914 employees.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium is based on market buzz and online information. It should not be considered as the actual listing price or valuation. Always refer to the RHP and seek advice from a financial expert before making any investment decisions.
- Clinical Research Expertise: Company bioequivalence ane clinical trials services ma specialize kare che, je pharma companies mate critical support che.
- Global Clientele: International pharma ane biotech clients sathe kaam karta hova thi revenue diversification ane foreign exposure male che.
- Regulated Industry Advantage: Clinical research sector ma entry barriers vadhu hoy, je thi established players ne advantage male che.
- Regulatory Dependency: Approvals ane compliance strict hova thi project timelines ane operations par impact thai shake che.
- Client Concentration Risk: Few large pharma clients par dependency hova thi revenue fluctuation no risk rahe che.
- Project-Based Revenue: Trials completion par income depend hoy, je thi revenue consistency vary thai shake che.
- Basil Private Limited
Veeda Clinical Research Limited
Link Intime India Private Limited